The global mRNA vaccines and RNAi therapeutics market revenue was around US$ 929.5 million in 2022 and is estimated to reach US$ 10,780.3 million by 2031, growing at a compound annual growth rate (CAGR) of 31.3% during the forecast period from 2023 to 2031.
Messenger Ribonucleic Acid (mRNA) refers to a single protein-coding gene in the genome that works as a base for protein synthesis within the cells. mRNA vaccines and RNAi therapeutics merge the desirable immunological properties and are prepared in laboratories utilizing mammalian cells. Some of the typical kinds of vaccines and therapeutics include non-replicating, self-amplifying, in vivo self-replicating, and in vitro dendritic cell non-replicating mRNA.
Market Driving Factors
The surge in the prevalence of chronic disease and infectious diseases is estimated to boost the market growth. mRNA vaccines and RNAi therapeutics have huge potential to resist against cancer and viral diseases owing to superiorities in efficacy, safety, and industrial production. Furthermore, there has been development of various types of mRNAs by sequence optimization to overcome the drawback of excessive mRNA instability, immunogenicity, and inefficiency.
Selectivity and target specialty of treatment and increase in awareness about vaccination are some RNAi and mRNA vaccine therapeutics that propel the market growth.
The high expense of research, the possibility of failure, and the difficulties in quantifying mRNA are expected to impede the market expansion.
Regional Analysis
North America dominated the market in terms of the highest share and is expected to maintain its dominance during the projection period. This can be majorly attributed to the increase in well-established healthcare systems, the surge in the number of geriatric patients, and supportive reimbursement guidelines in the healthcare system in the region.
Asia-Pacific dominates the market in terms of the fastest rate. This is majorly due to the surge in the prevalence of chronic diseases and the rise in the requirement of mRNA vaccines and RNAi therapeutics for the treatment of such disorders.
Segmentation Insights
Disease Type Insight
The hereditary transthyretin-mediated amyloidosis genetic segment dominates the market in terms of the major revenue share. This is due to the increase in demand for the treatment of amyloidosis owing to the surging prevalence and need for the treatment of fatal diseases. Additionally, the surge in awareness, enhancement in diagnostic procedures, progress in healthcare services, immediate economic growth in developing nations, and increase in R&D activities boost the market expansion.
The atherosclerotic cardiovascular disease segment is expected to dominate the market in terms of the fastest rate. This is due to the high consumption of cholesterol-lowering drugs by patients to lower blockages in arteries.
Route of Administration Insight
The IV infusion segment dominated the market in terms of the largest share and is estimated to maintain its dominance. This can be attributed to the surge in the adoption of IV infusion for the administration of therapeutics and vaccines.
The subcutaneous segment is estimated to dominate the market in terms of the growth rate. This is due to its price effectiveness of subcutaneous route of administration as compared to IV infusion.
End User Insight
The hospitals & clinics segment dominated the market in terms of revenue and is expected to maintain its dominance during the forecast period. This is due to a surge in number of patients with cancer, respiratory disease, and infectious disease.
The research institutes segment is expected to dominate the market in terms of the growth rate. This is mainly due to the partnership of research organizations and research institutes or collaborating with government bodies to handle the high price of research.
Prominent Companies
Segmentation Outline
The global mRNA vaccines and RNAi therapeutics market segmentation focuses on the Disease Type, Route of administration, End User, and Region.
By Disease Type
By Route of administration
By End User
By Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL mRNA VACCINES AND RNAi THERAPEUTICS MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY: mRNA VACCINES AND RNAi THERAPEUTICS MARKET
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
3.5 ANALYST TOOLS AND MODELS
4 GLOBAL mRNA VACCINES AND RNAi THERAPEUTICS MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS AND TRENDS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
4.5 MARKET GROWTH AND OUTLOOK
4.5.1 PRICE TREND ANALYSIS
4.5.2 OPPORTUNITY SHARE
5 GLOBAL mRNA VACCINES AND RNAi THERAPEUTICS MARKET, BY DISEASE TYPE
5.1 OVERVIEW
5.2 HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS GENETIC
5.3 ACUTE HEPATIC PORPHYRIA
5.4 PRIMARY HYPEROXALURIA TYPE 1
5.5 ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
6 GLOBAL mRNA VACCINES AND RNAi THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION
6.1 OVERVIEW
6.2 IV INFUSION
6.3 SUBCUTANEOUS
7 GLOBAL mRNA VACCINES AND RNAi THERAPEUTICS MARKET, BY END USER
7.1 OVERVIEW
7.2 RESEARCH INSTITUTES
7.3 HOSPITALS AND CLINICS
8 GLOBAL mRNA VACCINES AND RNAi THERAPEUTICS MARKET, BY GEOGRAPHY
8.1 OVERVIEW
8.2 NORTH AMERICA
8.2.1 NORTH AMERICA MARKET SNAPSHOT
8.2.2 U.S.
8.2.3 CANADA
8.2.4 MEXICO
8.3 EUROPE
8.3.1 EUROPE MARKET SNAPSHOT
8.3.2 WESTERN EUROPE
8.3.2.1 THE UK
8.3.2.2 GERMANY
8.3.2.3 FRANCE
8.3.2.4 ITALY
8.3.2.5 SPAIN
8.3.2.6 REST OF WESTERN EUROPE
8.3.3 EASTERN EUROPE
8.3.3.1 POLAND
8.3.3.2 RUSSIA
8.3.3.3 REST OF EASTERN EUROPE
8.4 ASIA PACIFIC
8.4.1 ASIA PACIFIC MARKET SNAPSHOT
8.4.2 CHINA
8.4.3 JAPAN
8.4.4 INDIA
8.4.5 AUSTRALIA & NEW ZEALAND
8.4.6 ASEAN
8.4.7 REST OF ASIA PACIFIC
8.5 MIDDLE EAST & AFRICA
8.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
8.5.2 UAE
8.5.3 SAUDI ARABIA
8.5.4 SOUTH AFRICA
8.5.5 REST OF MEA
8.6 SOUTH AMERICA
8.6.1 SOUTH AMERICA MARKET SNAPSHOT
8.6.2 BRAZIL
8.6.3 ARGENTINA
8.6.4 REST OF SOUTH AMERICA
9 GLOBAL mRNA VACCINES AND RNAi THERAPEUTICS MARKET COMPETITIVE LANDSCAPE
9.1 OVERVIEW
9.2 COMPANY MARKET RANKING
9.3 KEY DEVELOPMENT STRATEGIES
9.4 COMPETITIVE DASHBOARD
9.5 PRODUCT MAPPING
9.6 TOP PLAYER POSITIONING, 2022
9.7 COMPETITIVE HEATMAP
9.8 TOP WINNING STRATEGIES
10 COMPANY PROFILES
10.1 CUREVAC AG
10.1.1 OVERVIEW
10.1.2 FINANCIAL PERFORMANCE
10.1.3 PRODUCT OUTLOOK
10.1.4 KEY DEVELOPMENTS
10.1.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.2 ARCTURUS THERAPEUTICS
10.2.1 OVERVIEW
10.2.2 FINANCIAL PERFORMANCE
10.2.3 PRODUCT OUTLOOK
10.2.4 KEY DEVELOPMENTS
10.2.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.3 BIONTECH AG
10.3.1 OVERVIEW
10.3.2 FINANCIAL PERFORMANCE
10.3.3 PRODUCT OUTLOOK
10.3.4 KEY DEVELOPMENTS
10.3.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.4 NUTCRACKER
10.4.1 OVERVIEW
10.4.2 FINANCIAL PERFORMANCE
10.4.3 PRODUCT OUTLOOK
10.4.4 KEY DEVELOPMENTS
10.4.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.5 IN-CELL-ART
10.5.1 OVERVIEW
10.5.2 FINANCIAL PERFORMANCE
10.5.3 PRODUCT OUTLOOK
10.5.4 KEY DEVELOPMENTS
10.5.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.6 MODERNA THERAPEUTICS
10.6.1 OVERVIEW
10.6.2 FINANCIAL PERFORMANCE
10.6.3 PRODUCT OUTLOOK
10.6.4 KEY DEVELOPMENTS
10.6.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.7 TIBA BIOTECH
10.7.1 OVERVIEW
10.7.2 FINANCIAL PERFORMANCE
10.7.3 PRODUCT OUTLOOK
10.7.4 KEY DEVELOPMENTS
10.7.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.8 IONIS PHARMACEUTICALS INC
10.8.1 OVERVIEW
10.8.2 FINANCIAL PERFORMANCE
10.8.3 PRODUCT OUTLOOK
10.8.4 KEY DEVELOPMENTS
10.8.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.9 ETHRIS GMBH
10.9.1 OVERVIEW
10.9.2 FINANCIAL PERFORMANCE
10.9.3 PRODUCT OUTLOOK
10.9.4 KEY DEVELOPMENTS
10.9.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.10 SAREPTA THERAPEUTICS
10.10.1 OVERVIEW
10.10.2 FINANCIAL PERFORMANCE
10.10.3 PRODUCT OUTLOOK
10.10.4 KEY DEVELOPMENTS
10.10.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.11 SCM LIFE SCIENCES
10.11.1 OVERVIEW
10.11.2 FINANCIAL PERFORMANCE
10.11.3 PRODUCT OUTLOOK
10.11.4 KEY DEVELOPMENTS
10.11.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.12 ALNYLAM PHARMACEUTICALS
10.12.1 OVERVIEW
10.12.2 FINANCIAL PERFORMANCE
10.12.3 PRODUCT OUTLOOK
10.12.4 KEY DEVELOPMENTS
10.12.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.13 SANOFI AG
10.13.1 OVERVIEW
10.13.2 FINANCIAL PERFORMANCE
10.13.3 PRODUCT OUTLOOK
10.13.4 KEY DEVELOPMENTS
10.13.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.14 ETHERNA IMMUNOTHERAPIES
10.14.1 OVERVIEW
10.14.2 FINANCIAL PERFORMANCE
10.14.3 PRODUCT OUTLOOK
10.14.4 KEY DEVELOPMENTS
10.14.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
10.15 SANGAMO THERAPEUTICS INC.
10.15.1 OVERVIEW
10.15.2 FINANCIAL PERFORMANCE
10.15.3 PRODUCT OUTLOOK
10.15.4 KEY DEVELOPMENTS
10.15.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved